Abstract
Mass spectrometry-based technologies are increasingly utilized in drug discovery. Phosphoproteomics in particular has allowed for the efficient surveying of phosphotyrosine signaling pathways involved in various diseases states, most prominently in cancer. We describe a phosphotyrosine-based proteomics screening approach to identify signaling pathways and tyrosine kinase inhibitor targets in highly tumorigenic human lymphoma-like primary cells. We identified several receptor tyrosine kinase pathways and validated SRC family kinases (SFKs) as potential drug targets for targeted selection of small molecule inhibitors. BMS-354825 (dasatinib) and SKI-606 (bosutinib), second and third generation clinical SFK/ABL inhibitors, were found to be potent cytotoxic agents against tumorigenic cells with low toxicity to normal pediatric stem cells. Both SFK inhibitors reduced ERK1/2 and AKT phosphorylation and induced apoptosis. This study supports the adaptation of high-end mass spectrometry techniques for the efficient identification of candidate tyrosine kinases as novel therapeutic targets in primary cancer cell lines.
Keywords: Bosutinib, BMS-354825, dasatinib, kinase inhibitors, phosphoproteomics, SKI-606, Src family kinases.
Current Drug Discovery Technologies
Title:A Phosphoproteomics Approach to Identify Candidate Kinase Inhibitor Pathway Targets in Lymphoma-Like Primary Cell Lines
Volume: 10 Issue: 4
Author(s): Miliana Vojvodic, Loen M. Hansford, Olena Morozova, Kim M. Blakely, Paul Taylor, Kelly E. Fathers, Jason Moffat, Marco Marra, Kristen M. Smith, Michael F. Moran and David R. Kaplan
Affiliation:
Keywords: Bosutinib, BMS-354825, dasatinib, kinase inhibitors, phosphoproteomics, SKI-606, Src family kinases.
Abstract: Mass spectrometry-based technologies are increasingly utilized in drug discovery. Phosphoproteomics in particular has allowed for the efficient surveying of phosphotyrosine signaling pathways involved in various diseases states, most prominently in cancer. We describe a phosphotyrosine-based proteomics screening approach to identify signaling pathways and tyrosine kinase inhibitor targets in highly tumorigenic human lymphoma-like primary cells. We identified several receptor tyrosine kinase pathways and validated SRC family kinases (SFKs) as potential drug targets for targeted selection of small molecule inhibitors. BMS-354825 (dasatinib) and SKI-606 (bosutinib), second and third generation clinical SFK/ABL inhibitors, were found to be potent cytotoxic agents against tumorigenic cells with low toxicity to normal pediatric stem cells. Both SFK inhibitors reduced ERK1/2 and AKT phosphorylation and induced apoptosis. This study supports the adaptation of high-end mass spectrometry techniques for the efficient identification of candidate tyrosine kinases as novel therapeutic targets in primary cancer cell lines.
Export Options
About this article
Cite this article as:
Vojvodic Miliana, Hansford M. Loen, Morozova Olena, Blakely M. Kim, Taylor Paul, Fathers E. Kelly, Moffat Jason, Marra Marco, Smith M. Kristen, Moran F. Michael and Kaplan R. David, A Phosphoproteomics Approach to Identify Candidate Kinase Inhibitor Pathway Targets in Lymphoma-Like Primary Cell Lines, Current Drug Discovery Technologies 2013; 10 (4) . https://dx.doi.org/10.2174/15701638113109990001
DOI https://dx.doi.org/10.2174/15701638113109990001 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Activation of p53 in Cancer Cells
Current Pharmaceutical Design Anti-Cancer Therapy: Targeting the Mevalonate Pathway
Current Cancer Drug Targets Recent Patents Concerning Diagnostic and Therapeutic Applications of Aberrantly Methylated Sequences in Pancreatic Cancer
Recent Patents on DNA & Gene Sequences The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness
Current Drug Targets Utility of γH2AX as a Molecular Marker of DNA Double-Strand Breaks in Nuclear Medicine: Applications to Radionuclide Therapy Employing Auger Electron-Emitting Isotopes
Current Radiopharmaceuticals Role of Endothelial Progenitor Cell Mobilization After Percutaneous Angioplasty Procedure
Current Pharmaceutical Design A Case of Subcutaneous Phaeohyphomycosis Associated with Leprosy
Infectious Disorders - Drug Targets Exploratory Study on the Effects of Biodegradable Nanoparticles with Drugs on Malignant B Cells and on a Human/Mouse Model of Burkitt Lymphoma
Current Clinical Pharmacology The PI3K/AKT/mTOR-Signal Transduction Pathway as Drug Target in Triple-Negative Breast Cancer
Clinical Cancer Drugs Regulation of EMT by Notch Signaling Pathway in Tumor Progression
Current Cancer Drug Targets Natural Products As Antimitotic Agents
Current Topics in Medicinal Chemistry T Cell Tuning for Tumour Therapy: Enhancing Effector Function and Memory Potential of Therapeutic T cells
Current Gene Therapy The Potential of Microalgae for the Production of Bioactive Molecules of Pharmaceutical Interest
Current Pharmaceutical Biotechnology The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Indian Pediatric HIV Epidemic: A Systematic Review
Current HIV Research Editorial (Thematic Issue: From Gut Inflammation to Gastrointestinal Disorders Current Update on Pathophysiology, Molecular Mechanism and Pharmacological Treatment Modalities)
Current Pharmaceutical Design Serotonin as a Modulator of Immune Function: An Overview
Current Immunology Reviews (Discontinued) An Overview of Labeled Porphyrin Molecules in Medical Imaging
Recent Patents and Topics on Imaging (Discontinued) Targeting of NF-kappaB Signaling Pathway, other Signaling Pathways and Epigenetics in Therapy of Multiple Myeloma
Cardiovascular & Hematological Disorders-Drug Targets Aluminum Excytotoxicity and NeuroAutotoImmunity: The Role of the Brain Expression of CD32+ (FcγRIIa), ICAM-1+ and CD3ع in Aging
Current Aging Science